Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies (NASDAQ: AKTS) announced that its patented XBAW filters will be utilized in a new WiFi 6E router from a tier-1 OEM. The router will employ eight XBAW filters operating at 5.5 GHz and 6.5 GHz. Production of this router is anticipated to begin in early 2022, aligning with Akoustis's strategy to ramp up its production capacity to 500 million filters annually by the end of 2021. The approval of the 5.9 to 7.1 GHz spectrum by the FCC has significantly increased demand for high-performance coexistence filters, bolstering Akoustis's market position.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced participation in the Roth Virtual London Conference from June 21-23, 2021. The company is set to engage with investors through virtual meetings due to Covid-19 precautions. Akoustis is ramping production capacity at its New York facility to 500 million filters annually by the end of 2021, driven by demand for 5G and WiFi 6E solutions. They currently offer 15 commercial XBAW filters and plan to expand their product catalog, highlighting advancements in high-band RF filters for mobile and wireless applications.
Akoustis Technologies (NASDAQ: AKTS) announced that CEO Jeff Shealy will appear on Fox Business Network's The Claman Countdown at 3:30 PM EDT today. The company is ramping up volume production of its WiFi 6 tandem RF filter solutions and shipping 5G XBAW® filters. Akoustis plans to increase annual production capacity to 500 million filters by the end of 2021, driven by a growing sales funnel for 5G and WiFi 6E technologies. Currently, Akoustis has 15 commercial XBAW filters in its catalog and is set to introduce more solutions soon.
Akoustis Technologies (NASDAQ: AKTS) announced a visit from Senator Chuck Schumer to its semiconductor manufacturing facility in Canandaigua, NY. Schumer introduced the U.S. Innovation and Competition Act, which proposes $52 billion for semiconductor manufacturing and R&D programs in the U.S., aiming to make New York a hub for the industry. Jeff Shealy, CEO of Akoustis, expressed gratitude for the senator's support, highlighting the importance of on-shore manufacturing.
Akoustis plans to achieve 24/7 operation by the end of 2021 and aims to produce 500 million units annually.
Akoustis Technologies (NASDAQ: AKTS) announced participation in the Stifel 2021 Virtual Cross Sector Insight Conference on June 8, 2021. Senior management will host a webcast at 8:00 AM ET, available on their investor relations page. The company is ramping production capacity at its New York facility to 500 million filters per year by the end of 2021, in response to increasing demand for 5G and WiFi 6E technologies. Akoustis currently offers 15 commercial XBAW filters, with plans to introduce two new WiFi 6E coexistence filters, expanding their product catalog to 17.
Akoustis Technologies (NASDAQ: AKTS) will attend the 18th Annual Craig-Hallum Institutional Investor Conference on June 2, 2021, with virtual meetings due to COVID-19. The company is ramping up production of its 5G and WiFi 6E filter solutions, targeting an annual capacity of 500 million filters by the end of 2021. Akoustis currently has 15 commercial XBAW filters and plans to introduce two new WiFi 6E filters, expanding its product catalog to 17.
Akoustis Technologies (NASDAQ: AKTS) announced the inclusion of its patented XBAW® filters in a new WiFi 6E reference design by a leading SoC maker, marking its third partner for WiFi 6E since March. The 5.5 GHz and 6.5 GHz filter modules target advanced routers and connected devices. With FCC enabling new frequency bands, demand for Akoustis filters is set to grow. The company plans to increase its production capacity to 500 million filters annually by the end of 2021, supporting the expected demand for 5G and WiFi 6E solutions.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the 16th Annual Needham Virtual Technology & Media Conference on May 17-18, 2021. Management will present on May 18 at 8:00 am ET. The company continues to enhance its production capabilities, planning to increase annual output to 500 million filters at its New York facility by the end of 2021, driven by growing demand for 5G and WiFi 6E solutions. Currently, Akoustis has 15 commercial XBAW filters, with further innovations underway for the burgeoning RF filter market.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced participation in the 6th Annual Oppenheimer Emerging Growth Conference on May 11, 2021. Due to Covid-19, meetings will be held virtually. The Company is advancing its WiFi 6 tandem filter production and shipping multiple 5G small cell XBAW filters. Anticipating growth in 5G mobile and WiFi 6E, Akoustis plans to boost annual production capacity to 500 million filters by end of 2021. Currently, 15 filters are in their catalog, with the potential to add two more WiFi 6E filters soon.
Akoustis Technologies (NASDAQ: AKTS) introduced a new chip scale package (CSP) to enhance its XBAW filter product line for 5G mobile and WiFi 6E devices. The CSP is set to enter qualification in Q2 of 2021, with production anticipated in the latter half of the year. This development supports rapid prototyping and flexible capacity through both in-house and outsourced manufacturing. The company aims to boost its annual production capacity to 500 million filters by year-end, responding to a growing sales funnel in the 5G and WiFi markets.